Published in final edited form as:

Addict Behav. 2017 September ; 72: 33–40. doi:10.1016/j.addbeh.2017.03.011.

Emotion dysregulation explains the relation between insomnia symptoms and negative reinforcement smoking cognitions among daily smokers

Brooke Y. Kauffman^a, Samantha G. Farris^{a,b}, Candice A. Alfano^a, and Michael J. Zvolensky^{a,c,*}

^aUniversity of Houston, Department of Psychology, Houston, TX, United States

^bAlpert Medical School of Brown University, Department of Psychiatry and Human Behavior, Providence, RI, United States

^cThe University of Texas MD Anderson Cancer Center, Department of Behavioral Science, Houston, TX, United States

Abstract

Introduction—Insomnia co-occurs with smoking. However, mechanisms that may explain their comorbidity are not well known.

Method—The present study tested the hypothesis that insomnia would exert an indirect effect on negative reinforcement smoking processes via emotion dysregulation among 126 adult non-treatment seeking daily smokers (55 females; $M_{\text{age}} = 44.1$ years, $SD = 9.72$). Negative reinforcement smoking processes included negative reinforcement smoking outcome expectancies, negative reinforcement smoking motives, and two negative expectancies from brief smoking abstinence (somatic symptoms and harmful consequences).

Results—Insomnia symptoms yielded a significant indirect effect through emotion dysregulation for negative reinforcement smoking outcome expectancies, negative reinforcement smoking motives, and harmful consequences expectancies from brief smoking abstinence. In contrast to prediction, however, insomnia was not associated with somatic symptom expectancies from brief smoking abstinence through emotion dysregulation.

Conclusions—These data may suggest that the indirect effect of emotion dysregulation is more relevant to cognitive-affective negative reinforcement processes rather than somatic states. Overall, the present findings contribute to a growing body of literature linking emotion dysregulation as an

*Corresponding author at: The University of Houston, 126 Heyne Building, Houston, TX 77204-5502, United States. mjzvolen@central.uh.edu (M.J. Zvolensky).

Contributors

Authors Samantha Farris and Michael Zvolensky designed the study and wrote the protocol. Author Samantha Farris, Brooke Kauffman, and Michael Zvolensky conducted literature searches and provided summaries of previous research studies. Author Brooke Kauffman conducted the statistical analysis. Author Brooke Kauffman and Samantha Farris wrote the first draft of the manuscript and Michael Zvolensky mentored the team through the writing process. Author Candice Alfano also provided expertise of the literature and edits on the manuscript through the writing process. All authors contributed to and have approved the final manuscript.

Conflict of interest

All other authors declare that they have no conflicts of interest.

explanatory mechanism for insomnia and smoking and uniquely extend such work to an array of clinically significant negative reinforcement smoking processes.

Keywords

Insomnia; Emotion dysregulation; Smoking; Sleep; Tobacco

1. Introduction

Insomnia is characterized as difficulty falling asleep, staying asleep, early morning awakening, or non-restful sleep (Sateia, Doghramji, Hauri, & Morin, 2000). It is one of the most common health behavior problems in the United States (U.S.) with approximately 35% to 50% of the general population experiencing some form of insomnia symptoms (Buysse, 2013; Roth, 2007; USDHHS, 2004). The disorder poses a large economic burden on society, costing the U.S. an estimated \$65 billion dollars in health care costs and lost productivity annually (USDHHS, 2004). Furthermore, insomnia is associated with a number of negative physical and psychological problems, including a variety of physical illnesses (Mellinger, Balter, & Uhlenhuth, 1985), depression (Franzen & Buysse, 2008; Johnson, Roth, & Breslau, 2006; Ohayon, 2002; Ohayon, Caulet, & Lemoine, 1998), stress (Sheikh, Woodward, & Leskin, 2003), anxiety (Johnson et al., 2006; Ohayon, 2002; Papadimitriou & Linkowski, 2005), and a poor quality of life (Bolge, Doan, Kannan, & Baran, 2009; Sateia et al., 2000).

Insomnia often co-occurs with other problematic health behaviors (e.g., addictive disorders). For example, research has highlighted the substantive comorbidity of insomnia and smoking (Conroy & Arnedt, 2014). One epidemiological study of 769 participants found that 39% of light smokers and 33% of heavy smokers experienced chronic insomnia (i.e., difficulty initiating or maintaining sleep persisting for at least 6 months; Riedel, Durrence, Lichstein, Taylor, & Bush, 2004). Furthermore, available data suggest the relation between insomnia and smoking is complex and bi-directional (Wetter & Young, 1994), such that smoking may contribute to insomnia, and insomnia may promote continued smoking. For example, among smokers, tobacco withdrawal is associated with disrupted sleep (Rieder, Kunze, Groman, Kiefer, & Schoberberger, 2001) and desire to smoke during the sleep period (Scharf, Dunbar, & Shiffman, 2008). Conversely, greater levels of insomnia are associated with an increased risk for smoking lapse and relapse during quit attempts (Augustson et al., 2008; Boutou et al., 2008; Short et al., 2017). Indeed, smokers who report co-occurring night smoking and significant sleep disturbance are at greater risk for smoking postquit compared to smokers with neither risk factor (Peters, Fucito, Novosad, Toll, & O'Malley, 2011). Furthermore, existing work has found sleep disturbance may contribute to negative smoking outcomes after a quit attempt independent of sleep disturbances related to tobacco withdrawal (Augustson et al., 2008). Despite the interconnection between insomnia and smoking, surprisingly little empirical work has explored mechanisms underlying their association.

There is a need to explicate the processes governing associations between insomnia and smoking to clarify underlying factors that may help to explicate their comorbidity. Emotion

dysregulation is one possible factor. Emotion dysregulation reflects difficulties engaging a set of abilities wherein one can observe, understand, evaluate, and differentiate one's emotions and subsequently access strategies to regulate emotions and control behavioral responses (Gratz & Roemer, 2004; Tull & Aldao, 2015). Some initial work has begun to document relations between insomnia and emotion dysregulation among non-smokers. For instance, poorer sleep quality and shortened sleep duration are both robustly associated with emotion dysregulation (Palmer & Alfano, 2016). Experimental work has found that sleep loss impacts connections between the medial prefrontal cortex and amygdala, showing increases in emotional arousal to coincide with deficits in emotional control and monitoring (Yoo, Gujar, Hu, Jolesz, & Walker, 2007).

Theoretically, smokers experiencing insomnia symptoms may respond to internal sensations (e.g., somatic agitation associated with sleep disturbance) in a less adaptive fashion, resulting in greater subjective distress and a corresponding tendency to engage in negative reinforcement smoking behavior to manage such aversive states. For example, lesser ability to observe, understand, evaluate, differentiate, and regulate aversive emotional states would be expected to be strongly related to more aversive emotional symptoms (Paulus, Bakhshaie et al., 2016). As a result of such emotion dysregulation, these individuals may use smoking as a means of regulating negative emotions (Leventhal & Zvolensky, 2015). Indeed, emotion dysregulation is associated with early smoking lapse (Farris, Zvolensky, & Schmidt, 2016) among treatment-seeking smokers and is a mechanism that links negative emotional states to problematic substance use (e.g., symptoms of dependence; Paulus, Bakhshaie, et al., 2016; Paulus, Jardin, et al., 2016). To our knowledge, there has been only one test of an emotion dysregulation model for insomnia and smoking (Fillo et al., 2016). In this study, emotion dysregulation explained the association between sleep disturbances and less self-efficacy for remaining abstinent in relapse situations, more quit-related problems during past quit attempts, and less quit attempts >24 h among treatment-seeking smokers (Fillo et al., 2016).

Based upon theoretical models of emotion dysregulation and substance use (Leventhal & Zvolensky, 2015) and the findings of Fillo et al. (2016), there is a need to broaden our understanding of emotion dysregulation in the context of insomnia and smoking in at least three key ways. First, a central tenet of an emotion dysregulation perspective of insomnia and smoking rests on negative reinforcement processes; specifically, insomnia symptoms may interfere with smokers' capacity to regulate emotional states. As a result, smokers may seek out strategies to modulate distress (i.e., smoke), which may, in turn, maintain smoking behavior. Yet, past work has not explored negative reinforcement constructs in the context of insomnia-emotion dysregulation relations. Thus, a clinically and theoretically-relevant domain to evaluate would be whether emotion dysregulation as a global construct indirectly accounts for the relation between insomnia and negative reinforcement smoking processes, such as anticipated negative reinforcement smoking outcome expectancies (Brandon & Baker, 1991), negative reinforcement smoking motives (McCarthy, Curtin, Piper, & Baker, 2010), and two negative expectancies from brief (24-hour) smoking abstinence (somatic symptoms and harmful consequences; Abrams, Zvolensky, Dorman, Gonzalez, & Mayer, 2011). Furthermore, past work has highlighted smoking outcome expectancies and smoking motives as related although distinct constructs (Ikard, Green, & Horn, 1969). Specifically, negative reinforcement smoking outcome expectancies relates to *beliefs* that smoking will

help an individual cope with emotional distress (Brandon & Baker, 1991). Conversely, negative reinforcement smoking motives relates to an individual's *motivation* to smoke for reductions in emotional distress (Piper et al., 2004). Thus, work devoted to independently examining these unique negative reinforcement constructs is warranted to better understand the nature of smoking behavior.

Second, past work has not adjusted for psychopathology in models exploring insomnia-emotion dysregulation processes. Given that psychopathology co-varies with smoking (Ziedonis et al., 2008), insomnia (Papadimitriou & Linkowski, 2005), and emotion dysregulation (Tull & Aldao, 2015), it is necessary to adjust for psychiatric disorders when evaluating the validity of this model. Specifically, for the emotion dysregulation mediational model of insomnia-smoking to have maximal clinical significance, it would have to explain variance that is not simply accounted for by psychopathology.

Finally, since the Fillo et al. (2016) study included a sample of treatment-seeking smokers, there is need to test insomnia-emotion dysregulation relations among non-treatment seeking daily smokers in order to understand the generalizability of these findings. For example, treatment-seeking smokers tend to be a more severe population and may therefore be more apt to represent a biased sample when considered in the larger context of the smoking population (i.e., Berkson bias; Berkson, 1946; Rothman, Greenland, & Lash, 2008). Thus, to better ascertain the generalizability of past insomnia-emotion dysregulation work, tests among non-treatment seeking smokers would be timely and an important next research step.

Together, the current study tested the hypothesis that insomnia would exert an indirect effect on negative reinforcement smoking processes via emotion dysregulation (see Fig. 1). Specifically, insomnia was expected to be positively associated with emotion dysregulation, which, in turn, would be associated with smoking criterion variables. In the current study, four clinically significant criterion variables identified in past work were evaluated: negative reinforcement smoking outcome expectancies, negative reinforcement smoking motives, and two negative expectancies from brief smoking abstinence (somatic symptoms and harmful consequences). It was expected that an effect of insomnia via emotion dysregulation would be evident on all criterion measures over and above variance accounted for by participant sex, number of cigarettes smoked per day (i.e., smoking rate), and psychopathology.

2. Materials and method

2.1. Participants

Participants were 126 adult daily non-treatment seeking smokers (55 females; $M_{\text{age}} = 44.1$ years, $SD = 9.72$). The racial composition of the sample was African American (64.3%), Caucasian (29.4%), Hispanic (4.8%), American Indian/Alaska Native (1.6%), Asian American (0.8%), and 4% 'Other.' On average, participants reported smoking 15.1 cigarettes per day ($SD = 6.08$), initiated smoking at age 16.2 ($SD = 6.56$), and reported smoking for 23.6 years ($SD = 10.91$). The average score on the Fagerström Test for Nicotine Dependence (FTND; Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) was 4.7 ($SD = 1.49$), indicating low to moderate levels of tobacco dependence. Smoking status was confirmed by carbon monoxide (CO) sample analysis of expired breath sample ($M = 22.6$ ppm; $SD =$

11.43), which is above the 10 ppm established cut-off for determining a positive smoking status (Cocores, 1993). Regarding current (past-year) psychopathology, 39.7% ($n = 50$) met criteria for one or more diagnoses (range 1–4 diagnoses), which is not uncommon for this population (Centers for Disease Control and Prevention, 2013). Current psychopathology included: posttraumatic stress disorder (30%), major depressive disorder (22%), specific phobia (20%), alcohol abuse/dependence (14%), panic disorder with/without agoraphobia (10%), dysthymia disorder (10%), cannabis abuse/dependence (10%), opioid abuse/dependence (10%), social anxiety disorder (8%), cocaine abuse/dependence (8%), bipolar I disorder (full remission; 4%), bipolar II disorder (4%), mood disorder NOS (4%), generalized anxiety disorder (4%), eating disorder NOS (4%), obsessive-compulsive disorder (2%), bulimia nervosa (2%), sedative, hypnotic, anxiolytic dependence (2%), and poly-substance dependence (2%).

2.2. Measures

A *Demographics Questionnaire* was used to collect demographic data including participant sex, age, and race.

The *Structured Clinical Interview for DSM-IV Diagnosis of Axis I Disorders Non-Patient Version (SCID-NP)* (First, Spitzer, Gibbon, & Williams, 2007) was used to evaluate the presence of current (past year) psychological disorders, and are reported for descriptive purposes. Additionally, presence/absence of current (past year) psychopathology coded yes (1) or no (0). The interviews were administered by highly-trained post-baccalaureate research assistants and supervised by the study principal investigator (second author).

Number of cigarettes smoked per day was assessed with the *Timeline Follow-back (TLFB)*, a calendar-based assessment that assesses the quantity and frequency of cigarette use during the seven days prior to the in-person assessment. The TLFB has demonstrated good reliability and validity (Brown et al., 1998).

The *Smoking History Questionnaire (SHQ)* (Brown, Lejuez, Kahler, & Strong, 2002), a 30-item self-report measure of descriptive lifetime smoking history, was utilized to describe the sample in terms of smoking rate, age of smoking initiation, and total years of regular smoking.

A *Vitalograph BreathCO* carbon monoxide (CO; Vitalograph Inc., Lenexa, Kansas) monitor was used to measure the amount of carbon monoxide (in parts per million [ppm]) in an expired breath sample, as a biochemical verification of smoking status.

Level of tobacco dependence was assessed with the *Fagerström Test for Nicotine Dependence (FTND)* (Heatherton et al., 1991), a 6-item self-report assessment of gradations in tobacco dependence. Scores range from 0 to 10 with higher scores indicating higher levels of physiological dependence on tobacco. The FTND items have high test-retest reliability (Pomerleau, Carton, Lutzke, Flessland, & Pomerleau, 1994), acceptable levels of internal consistency, and is closely related to key smoking variables (e.g., saliva cotinine; Heatherton et al., 1991). Internal consistency in FTND items the current sample was low (Cronbach's α

= 0.43), which is not uncommon for this measure (Korte, Capron, Zvolensky, & Schmidt, 2013).

Insomnia symptoms were assessed using a subscale from the *Inventory of Depression and Anxiety Symptoms (IDAS)*; Watson et al., 2007). The IDAS is a 64-item self-report assessment of major depression and related anxiety disorders. Respondents are asked to rate the degree to which they have experienced symptoms within the past two weeks, rated on a 5-point Likert-type scale from 1 (*not at all*) to 5 (*extremely*). The Insomnia subscale (6 items; e.g., “I had trouble falling asleep”) items are summed to derive an index of insomnia symptoms, with higher scores indicative of greater insomnia symptoms in the past two weeks. This subscale has strong psychometric properties including, test-retest reliability, internal consistency, and discriminant validity (Watson et al., 2007). Internal consistency for the Insomnia subscale in the current sample was excellent (Cronbach's $\alpha = 0.92$).

The *Difficulties in Emotion Regulation Scale (DERS)*; Gratz & Roemer, 2004) is a 36-item self-report measure used to assess how often respondents experience dysregulated emotional states. Specifically, the DERS assesses six subscale facets which can be summed to create a total score: Non-Acceptance of Emotional Responses, Difficulties Engaging in Goal-Directed Behavior, Impulse Control Difficulties, Lack of Emotional Awareness, Access to Emotion Regulation Strategies, and Lack of Emotional Clarity. Items are rated on a 5-point Likert-type scale from 1 (*almost never*) to 5 (*almost always*). The total score can be derived, with higher values indicating greater emotion dysregulation (possible range = 36–180). The DERS items have strong psychometric properties (Gratz & Roemer, 2004; Whiteside et al., 2007). Internal consistency for the DERS total score was excellent (Cronbach's $\alpha = 0.95$).

The *Smoking Consequences Questionnaire (SCQ)*; Brandon & Baker, 1991) is a 50-item self-report measure used to assess the expected consequences of smoking a cigarette. Items are rated on a 10-point Likert-type scale ranging from 0 (*completely unlikely*) to 9 (*completely likely*). The SCQ measure and its constituent factors have demonstrated sound psychometric properties (Brandon & Baker, 1991; Buckley et al., 2005; Downey & Kilbey, 1995). In the current study, items from the Negative Reinforcement subscale (e.g., “If I am disappointed in myself, a good smoke can help”) were computed (12 items) and used in the current analyses. Internal consistency for these items was excellent (Cronbach's $\alpha = 0.95$).

The *Wisconsin Inventory of Smoking Dependence Motives (WISDM)*; Piper et al., 2004) is a 64-item self-report measure designed to assess 13 different theoretically derived motivational domains related to smoking. Items are rated on a 7-point Likert-type scale ranging from 1 (*not true of me at all*) to 7 (*extremely true of me*). In the current study, the Negative Reinforcement subscale, which includes 6 items, was used (e.g., “I reach for cigarettes when I feel irritable”). The WISDM subscales have demonstrated acceptable levels of internal consistency (Piper et al., 2004). In the current study, internal consistency for the Negative Reinforcement subscale items was excellent (Cronbach's $\alpha = 0.92$).

The *Smoking Abstinence Expectancies Questionnaire (SAEQ)*; Abrams et al., 2011) is a 28-item self-report measure that assesses consequences to be expected as a result of acute

smoking abstinence (i.e., stop smoking cigarettes/using nicotine for one day). Items are rated in terms of expected likelihood on a scale from 0 (*very unlikely*) to 6 (*very likely*). In the current study, the somatic symptoms (e.g., “My chest would feel tight”; $\alpha = 0.82$) and harmful consequences (e.g., “I would feel like I’m going crazy”; $\alpha = 0.86$) subscales were used, consistent with past work (Farris, Langdon, DiBello, & Zvolensky, 2015).

2.3. Procedure

Adult daily smokers were recruited for an experimental study on “smoking behavior” (Farris & Zvolensky, 2016) via flyers posted in community areas and college campuses, newspaper advertisements, webpage announcements (e.g. university website, [Craigslist.com](https://www.craigslist.com)), and word-of-mouth. Community-recruited smokers who were between 18 and 65 years of age, reported smoking 10 or more cigarettes per day for at least one year, and smoked within the first 30 min of waking in the morning, were invited for a baseline assessment to determine eligibility for the experimental study (described in Farris & Zvolensky, 2016). The current study is a secondary analysis of data from all participants who completed the baseline assessment, regardless of if they were deemed eligible for the experimental phase of the study. Participants were compensated \$25 for completing the baseline assessment. All participants provided written, informed consent prior to initiation of any study procedures, and this study protocol was approved by the Institutional Review Board where the study took place.

2.4. Analytic strategy

Data were first checked for the presence of multivariate outliers; no outliers were detected. Next, sample descriptive statistics and zero-order correlations among study variables were examined. Primary analyses included regression-based path models. In all models, covariates included participant sex (coded: 0 = male and 1 = female), number of cigarettes smoked per day (per the TLFB), and presence/absence of current (past year) psychopathology (coded: 0 = no and 1 = yes). The data analytic strategy utilized (Hayes, 2009; Preacher & Hayes, 2004) allows for estimation and significance testing of the total indirect (mediation) effects through bootstrapping. Bootstrapping generates an empirical representation of the sampling distribution of the indirect effect, from which a confidence interval can be generated (Hayes, 2009). Analyses were conducted using PROCESS, a conditional process modeling program that utilizes an ordinary least squares-based path analytical framework to test for both direct and indirect effects (Hayes, 2013). Conservative confidence intervals (99%) were specified to adjust for Type I error rate inflation (Hayes & Preacher, 2014); the CIs for the indirect effects were estimated with bootstrapped analyses (10,000 resamples) as recommended (Hayes, 2009; Preacher & Hayes, 2004; Preacher & Hayes, 2008). Effect sizes (κ^2) were calculated for each indirect effect per recommendations of Preacher and Kelley (2011). This value can be interpreted in a similar regard as squared correlation coefficients, as outlined by Cohen (1988).

3. Results

3.1. Bi-variate relations

Zero-order correlations among all study variables are presented in Table 1. Average IDAS-Insomnia scores in the current study ($M = 12.33$, $SD = 6.28$) were comparable to normative scores for community-recruited individuals ($M = 12.7$, $SD = 5.7$; Watson et al., 2007).

Insomnia symptoms were positively correlated with emotion dysregulation ($r = 0.57$) and all criterion variables (r 's = 0.20–0.37). Emotion dysregulation was positively correlated with all criterion variables (r 's = 0.36–0.50).

3.2. Indirect effects

Regression results are presented in Table 2. For negative reinforcement smoking outcome expectancies, the total effects model with insomnia symptoms and covariates in the model accounted for significant variance ($R^2 = 0.19$, $F[4, 121] = 7.10$, $p < 0.001$). The full model with emotion dysregulation was significant ($R^2 = 0.29$, $F[5, 120] = 9.78$, $p < 0.001$). In the test of the indirect effect, results indicated that insomnia symptoms were associated with negative reinforcement smoking outcome expectancies, which indirectly occurred through the effect of emotion dysregulation ($a * b = 0.08$, $SE = 0.03$, $CI_{99\%} = 0.030, 0.169$). The size of the indirect effect was medium to large ($\kappa^2 = 0.22$).

In terms of negative reinforcement smoking motives, the total effect model accounted for significant variance ($R^2 = 0.14$, $F[4, 121] = 4.76$, $p = 0.001$). The model with emotion dysregulation accounted for additional variance for negative reinforcement smoking motives ($R^2 = 0.20$, $F[5, 120] = 6.07$, $p < 0.001$). The test of the indirect effect indicated that insomnia symptoms were associated with negative reinforcement smoking motives indirectly through the effect of emotion dysregulation ($a * b = 0.05$, $SE = 0.02$, $CI_{99\%} = 0.009, 0.098$). The size of the indirect effect was medium to large ($\kappa^2 = 0.16$).

In regard to negative expectancies of somatic symptom expectancies from brief smoking abstinence, the total effects model with insomnia symptoms and all covariates in the model accounted for significant variance ($R^2 = 0.21$, $F[4, 121] = 8.15$, $p < 0.001$). The full model with the addition of emotion dysregulation accounted for additional variance ($R^2 = 0.23$, $F[5, 120] = 7.18$, $p < 0.001$). In the test of the indirect effect through emotion dysregulation, results indicated that insomnia symptoms were not significantly associated with somatic symptom expectancies from brief smoking abstinence ($a * b = 0.11$, $SE = 0.08$, $CI_{99\%} = -0.070, 0.338$). The size of the indirect effect was medium to large ($\kappa^2 = 0.11$).

The total effects model for harmful consequences expectancies from brief smoking abstinence accounted for significant variance ($R^2 = 0.22$, $F[4, 121] = 8.56$, $p < 0.001$). The full model including emotion dysregulation was significant ($R^2 = 0.31$, $F[5, 120] = 10.90$, $p < 0.001$). In regard to the indirect effect, insomnia symptoms significantly predicted harmful consequences expectancies from brief smoking abstinence indirectly through emotion dysregulation ($a * b = 0.29$, $SE = 0.10$, $CI_{99\%} = 0.061, 0.588$). The size of the indirect effect was medium to large ($\kappa^2 = 0.22$).

3.3. Specificity analyses

To further strengthen the interpretation of results, alternative models were tested by reversing the proposed mediator for each of the three significant models (Preacher & Hayes, 2004); specifically, emotion dysregulation was the predictor, insomnia was the indirect variable, and all three criterion variables remained the same. The indirect effects of the alternate models were non-significant for negative reinforcement smoking outcome expectancies ($a * b = 0.00$, $SE = 0.01$, $CI_{99\%} = -0.015, 0.016$), smoking motives ($a * b = 0.00$, $SE = 0.00$, $CI_{99\%} = -0.012, 0.011$), and harmful consequences expectancies from brief smoking abstinence ($a * b = 0.01$, $SE = 0.02$, $CI_{99\%} = -0.045, 0.062$).

4. Discussion

Insomnia often co-occurs with smoking (Riedel et al., 2004) and there is need to explicate the processes governing these associations toward clarifying underlying factors that explicate their comorbidity. The current study expanded upon the literature by examining whether emotion dysregulation explained, in part, the relationship between insomnia and negative reinforcement smoking outcome expectancies, negative reinforcement smoking motives, and negative expectancies from brief smoking abstinence (somatic symptoms and harmful consequences).

Consistent with prediction, insomnia symptoms yielded a significant indirect effect through emotion dysregulation for negative reinforcement smoking outcome expectancies, negative reinforcement smoking motives, and harmful consequences expectancies from brief smoking abstinence. Notably, the indirect effects were of medium to large size for all criterion variables ($\kappa^2 = 0.11-0.22$). These results are consistent with the hypothesis that insomnia symptoms are related to emotion dysregulation (the ‘*a*’ path), which in turn, is related to a variety of negative reinforcement smoking processes (the ‘*b*’ path). Notably, the observed indirect effects were evident after adjusting for the influence of factors known to correlate with the severity of smoking behavior and insomnia, including participant sex, number of cigarettes smoked per day, and psychopathology. The current findings also are in line with past work that found emotion dysregulation mediated the association between insomnia and self-efficacy for remaining abstinent in relapse situations, prior quit-related problems, and presence of a prior quit attempt >24 h among treatment-seeking smokers (Fillo et al., 2016). Yet, in contrast to prediction, insomnia was not associated with somatic symptom expectancies from brief smoking abstinence through the indirect effect of emotion dysregulation. These data may suggest that the indirect effect of emotion dysregulation is more relevant to cognitive-affective negative reinforcement processes rather than somatic states. For example, emotion dysregulation may be more pertinent to disrupting cognitive (e.g., “Smoking helps me think more clearly”) and affective states (e.g., “I need a cigarette now to calm my nerves”) than those that are more physiologic in nature (e.g., “Smoking makes me less aroused”). Although speculative, future work could compare cognitive-affective versus somatic negative reinforcement models to better gauge the applicability of this perspective to models of insomnia-smoking comorbidity.

As data were collected at one-time point, competing models were run to examine potential model misspecification. Specifically, for each hypothesized model (testing the indirect effect

of insomnia via emotion dysregulation), competing models were run. The competing models yielded non-significant indirect effects, adding confidence to the hypothesized model testing the indirect association of insomnia via emotion dysregulation. Overall, the regulation of emotions may represent an important intermediate construct linking insomnia to negative reinforcement cognitive-affective based smoking processes. Indeed, the present data suggest insomnia is related to emotion dysregulation, which, in turn, may affect negative reinforcement smoking outcome expectancies, negative reinforcement smoking motives, and negative expectancies from brief smoking abstinence (harmful consequences). Based upon these findings, future longitudinal work is needed to further evaluate this model.

The results from the present investigation may serve to conceptually inform the development of specialized intervention strategies for smokers prone to experiencing insomnia symptoms. For example, it may be beneficial to compliment smoking cessation treatments with the implementation of an integrated sleep intervention. Preliminary work has found that an integrated smoking-sleep intervention improved insomnia symptoms among smokers compared to smoking cessation counseling alone (Fucito et al., 2014). Thus, it may be plausible that, among smokers, integrating a sleep component in standard smoking cessation treatment may yield improvements in the ability to effectively regulate emotions as a result of a reduction in insomnia symptoms. Consequently, such improvements in emotion regulation may facilitate positive smoking outcomes. Furthermore, for smokers with insomnia symptoms, it may be advisable to understand and clinically address emotion dysregulation in order to enhance psychological flexibility related to maladaptive smoking cognitions (e.g., “I need a cigarette to cope with my (stressful) life”) and facilitate change in smoking behavior. For example, these results suggest that targeting and improving emotion dysregulation may have benefits in terms of addressing smoking behavior. Such an approach would be consistent with intervention work on emotion dysregulation and substance use (e.g., Berking et al., 2011). For example, changes in the use of maladaptive emotion regulation strategies over the course of treatment have been shown to predict changes in anxiety/stress and alcohol-related psychopathology (Conklin et al., 2015). It is possible that tailoring these treatments to smokers with insomnia would offer a novel and more personalized approach to improve behavioral health and change smoking behavior.

There are several interpretive caveats to the present study. First, given the cross-sectional nature of these data, causal relations cannot be explicated. Tests were based on a theoretical framework supported by extant empirical data, but did not allow for testing of temporal sequencing. Based upon the present results, future prospective studies are necessary to determine the directional effects of these relations. Second, our sample consisted of community-recruited, daily cigarette smokers with moderate levels of nicotine dependence. Future studies may benefit by sampling from lighter and heavier smoking populations to ensure the generalizability of the results to the general smoking population. Third, as the key variables were assessed via self-report, there is the possibility that the observed relations were in part a function of shared method variance. Future research would benefit by employing a multi-method assessment approach to cross-index the nature of the relations observed in the current report. In particular, utilization of an objective measure of sleep such as actigraphy would be more ideal than sole reliance on subjective sleep reports. Fourth, although the current study with emotion dysregulation modeled as a global construct was

significant, some work suggests that specific facets of emotion dysregulation may differentially relate to aspects of smoking. For example, emotional non-acceptance (i.e., the tendency to judge or negatively evaluate one's emotions) has been found to play a role in recency of smoking (Adams, Tull, & Gratz, 2012). Because there was highly limited study of emotion dysregulation, smoking, and sleep behavior, we did not have specific a priori hypotheses (or, any theoretical reason) for sub-facets of emotion dysregulation to be differentially relevant in the current tests. Based on the present findings, further work could examine the nature of specific emotion regulation strategies (i.e., Non-Acceptance of Emotional Responses, Difficulties Engaging in Goal-Directed Behavior, Impulse Control Difficulties, Lack of Emotional Awareness, Access to Emotion Regulation Strategies, and Lack of Emotional Clarity) among smokers within the context of insomnia. Finally, the current study controlled for the presence/absence of current (past year) psychopathology. Future work should consider controlling for general negative affectivity to address populations experiencing subclinical or remitted psychopathology.

4.1. Conclusions

Overall, the present study serves as an initial exploration into the association between insomnia, emotion dysregulation, and negative reinforcement smoking processes. There was consistent empirical evidence of indirect associations of insomnia via emotion dysregulation. Accordingly, if replicated, intervention programs for smokers with insomnia may benefit from consideration of emotion regulation therapeutic tactics.

Acknowledgments

Role of funding sources

This work was funded by a pre-doctoral National Research Service Award awarded to Dr. Samantha Farris (F31-DA035564). The research described in this paper was also supported in part by a grant to Dr. Samantha Farris from the American Psychological Association. The funding agencies had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.

References

- Abrams K, Zvolensky MJ, Dorman L, Gonzalez A, Mayer M. Development and validation of the smoking abstinence expectancies questionnaire. *Nicotine & Tobacco Research*. 2011; 13(12):1296–1304. <http://dx.doi.org/10.1093/ntr/ntr184>. [PubMed: 21994341]
- Adams CE, Tull MT, Gratz KL. The role of emotional nonacceptance in the relation between depression and recent cigarette smoking. *American Journal on Addictions*. 2012; 21(4):293–301. <http://dx.doi.org/10.1111/j.1521-0391.2012.00238.x>. [PubMed: 22691007]
- Augustson EM, Wanke KL, Rogers S, Bergen AW, Chatterjee N, Synder K, et al. Predictors of sustained smoking cessation: A prospective analysis of chronic smokers from the alpha-tocopherol beta-carotene cancer prevention study. *American Journal of Public Health*. 2008; 98(3):549–555. <http://dx.doi.org/10.2105/ajph.2005.084137>. [PubMed: 17600267]
- Berking M, Margraf M, Ebert D, Wupperman P, Hofmann SG, Junghanns K. Deficits in emotion-regulation skills predict alcohol use during and after cognitive-behavioral therapy for alcohol dependence. *Journal of Consulting and Clinical Psychology*. 2011; 79(3):307–318. <http://dx.doi.org/10.1037/a0023421>. [PubMed: 21534653]
- Berkson J. Limitations of the application of fourfold table analysis to hospital data. *Biometrics Bulletin*. 1946; 2(3):47–53. [PubMed: 21001024]

- Bolge SC, Doan JF, Kannan H, Baran RW. Association of insomnia with quality of life, work productivity, and activity impairment. *Quality of Life Research*. 2009; 18(4):415–422. <http://dx.doi.org/10.1007/s11136-009-9462-6>. [PubMed: 19288223]
- Boutou AK, Tsiata EA, Pataka A, Kontou PK, Pitsiou GG, Argyropoulou P. Smoking cessation in clinical practice: Predictors of six-month continuous abstinence in a sample of Greek smokers. *Primary Care Respiratory Journal: Journal of the General Practice Airways Group*. 2008; 17(1):32–38. <http://dx.doi.org/10.3132/pcrj.2008.00009>.
- Brandon TH, Baker TB. The smoking consequences questionnaire: The subjective expected utility of smoking in college students. *Psychological Assessment: A Journal of Consulting and Clinical Psychology*. 1991; 3(3):484.
- Brown RA, Burgess ES, Sales SD, Whiteley JA, Evans DM, Miller IW. Reliability and validity of a smoking timeline follow-back interview. *Psychology of Addictive Behaviors*. 1998; 12(2):101–112. <http://dx.doi.org/10.1037/0893-164X.12.2.101>.
- Brown RA, Lejuez CW, Kahler CW, Strong DR. Distress tolerance and duration of past smoking cessation attempts. *Journal of Abnormal Psychology*. 2002; 111:180–185. [PubMed: 11866171]
- Buckley TC, Kamholz BW, Mozley SL, Gulliver SB, Holohan DR, Helstrom AW, et al. A psychometric evaluation of the smoking consequences questionnaire-adult in smokers with psychiatric conditions. *Nicotine & Tobacco Research*. 2005; 7(5):739–745. <http://dx.doi.org/10.1080/14622200500259788>. [PubMed: 16191745]
- Buyse DJ. Insomnia. *Journal of the American Medical Association*. 2013; 309(7):706–716. <http://dx.doi.org/10.1001/jama.2013.193>. [PubMed: 23423416]
- Centers for Disease Control and Prevention, C. Vital signs: Current cigarette smoking among adults aged 18 years with mental illness — United States, 2009–2011. *Morbidity and Mortality Weekly Report*. 2013; 65(05):81–87.
- Cocores J. Nicotine dependence. Diagnosis and treatment. *Recent Advances in Addictive Disorders*. 1993; 16(1):49–60.
- Cohen, J. *Statistical power analysis for the behavioral sciences*. 2. New York: NY: Academic Press; 1988.
- Conklin LR, Cassiello-Robbins C, Brake CA, Sauer-Zavala S, Farchione TJ, Ciraulo DA, et al. Relationships among adaptive and maladaptive emotion regulation strategies and psychopathology during the treatment of comorbid anxiety and alcohol use disorders. *Behaviour Research and Therapy*. 2015; 73:124–130. <http://dx.doi.org/10.1016/j.brat.2015.08.001>. [PubMed: 26310363]
- Conroy DA, Arndt JT. Sleep and substance use disorders: An update. *Current Psychiatry Reports*. 2014; 16(10):487. <http://dx.doi.org/10.1007/s11920-014-0487-3>. [PubMed: 25135784]
- Downey KK, Kilbey MM. Relationship between nicotine and alcohol expectancies and substance dependence. *Experimental and Clinical Psychopharmacology*. 1995; 3(2):174–182. <http://dx.doi.org/10.1037/1064-1297.3.2.174>.
- Farris SG, Zvolensky MJ. An experimental test of the effect of acute anxious arousal and anxiety sensitivity on negative reinforcement smoking. *Journal of Psychopharmacology*. 2016; 30(7):641–653. <http://dx.doi.org/10.1177/0269881116642880>. [PubMed: 27097735]
- Farris SG, Langdon KJ, DiBello AM, Zvolensky MJ. Why do anxiety sensitive smokers perceive quitting as difficult? The role of expecting “interoceptive threat” during acute abstinence. *Cognitive Therapy and Research*. 2015; 39(2):236–244. <http://dx.doi.org/10.1007/s10608-014-9644-6>.
- Farris SG, Zvolensky MJ, Schmidt NB. Difficulties with emotion regulation and psychopathology interact to predict early smoking cessation lapse. *Cognitive Therapy and Research*. 2016; 40(3):357–367. <http://dx.doi.org/10.1007/s10608-015-9705-5>. [PubMed: 27239081]
- Fillo J, Alfano CA, Paulus DJ, Smits JAJ, Davis ML, Rosenfield D, et al. Emotion dysregulation explains relations between sleep disturbance and smoking quit-related cognition and behavior. *Addictive Behaviors*. 2016; 57:6–12. <http://dx.doi.org/10.1016/j.addbeh.2016.01.013>. [PubMed: 26827153]
- First, MB., Spitzer, RL., Gibbon, M., Williams, JB. *Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition (SCIDI/NP)*. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2007.

- Franzen PL, Buysse DJ. Sleep disturbances and depression: Risk relationships for subsequent depression and therapeutic implications. *Dialogues in Clinical Neuroscience*. 2008; 10(4):473–481. [PubMed: 19170404]
- Fucito LM, Redeker NS, Ball SA, Toll BA, Ikomi JT, Carroll KM. Integrating a behavioural sleep intervention into smoking cessation treatment for smokers with insomnia: A randomised pilot study. *Journal of Smoking Cessation*. 2014; 9(1):31–38. <http://dx.doi.org/10.1017/jsc.2013.19>. [PubMed: 24995044]
- Gratz KL, Roemer L. Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale. *Journal of Psychopathology and Behavioral Assessment*. 2004; 26(1):41–54.
- Hayes AF. Beyond Baron and Kenny: Statistical mediation analysis in the new millennium. *Communication Monographs*. 2009; 76(4):408–420. <http://dx.doi.org/10.1080/03637750903310360>.
- Hayes, AF. Introduction to mediation, moderation, and conditional process analysis: A regression-based approach. New York: Guilford Press; 2013.
- Hayes AF, Preacher KJ. Statistical mediation analysis with a multicategorical independent variable. *The British Journal of Mathematical and Statistical Psychology*. 2014; 67(3):451–470. <http://dx.doi.org/10.1111/bmsp.12028>. [PubMed: 24188158]
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: A revision of the Fagerstrom tolerance questionnaire. *The British Journal of Addiction to Alcohol and Other Drugs*. 1991; 86(9):1119–1127.
- Ikard FF, Green DE, Horn D. A scale to differentiate between types of smoking as related to the management of affect. *International Journal of the Addictions*. 1969; 4(4):649–659.
- Johnson EO, Roth T, Breslau N. The association of insomnia with anxiety disorders and depression: Exploration of the direction of risk. *Journal of Psychiatric Research*. 2006; 40(8):700–708. <http://dx.doi.org/10.1016/j.jpsychires.2006.07.008>. [PubMed: 16978649]
- Korte KJ, Capron DW, Zvolensky M, Schmidt NB. The Fagerstrom test for nicotine dependence: Do revisions in the item scoring enhance the psychometric properties? *Addictive Behaviors*. 2013; 38(3):1757–1763. <http://dx.doi.org/10.1016/j.addbeh.2012.10.013>. [PubMed: 23254226]
- Leventhal AM, Zvolensky MJ. Anxiety, depression, and cigarette smoking: A transdiagnostic vulnerability framework to understanding emotion-smoking comorbidity. *Psychological Bulletin*. 2015; 141(1):176–212. <http://dx.doi.org/10.1037/bul0000003>. [PubMed: 25365764]
- McCarthy, DE., Curtin, JJ., Piper, ME., Baker, TB. Negative reinforcement: Possible clinical implications of an integrative model. In: Kassel, JD., editor. *Substance abuse and emotion*. Washington, DC: American Psychological Association; 2010. p. 15–42.
- Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. *Archives of General Psychiatry*. 1985; 42(3):225–232. [PubMed: 2858188]
- Ohayon MM. Epidemiology of insomnia: What we know and what we still need to learn. *Sleep Medicine Reviews*. 2002; 6(2):97–111. <http://dx.doi.org/10.1053/smr.2002.0186>. [PubMed: 12531146]
- Ohayon MM, Caulet M, Lemoine P. Comorbidity of mental and insomnia disorders in the general population. *Comprehensive Psychiatry*. 1998; 39(4):185–197. [PubMed: 9675502]
- Palmer, CA., Alfano, CA. Sleep and emotion regulation: An organizing, integrative review. *Sleep Medicine Reviews*. 2016. <http://dx.doi.org/10.1016/j.smr.2015.12.006>
- Papadimitriou GN, Linkowski P. Sleep disturbance in anxiety disorders. *International Review of Psychiatry*. 2005; 17(4):229–236. <http://dx.doi.org/10.1080/09540260500104524>. [PubMed: 16194794]
- Paulus DJ, Bakhshaie J, Lemaire C, Garza M, Ochoa-Perez M, Valdivieso J, et al. Negative affectivity and problematic alcohol use among Latinos in primary care: The role of emotion dysregulation. *Journal of Dual Diagnosis*. 2016; 0 <http://dx.doi.org/10.1080/15504263.2016.1172897>.
- Paulus DJ, Jardin C, Bakhshaie J, Sharp C, Woods SP, Lemaire C. Anxiety sensitivity and hazardous drinking among persons living with HIV/AIDS: An examination of the role of emotion dysregulation. *Addictive Behaviors*. 2016; 63:141–148. [PubMed: 27497249]

- Peters EN, Fucito LM, Novosad C, Toll BA, O'Malley SS. Effect of night smoking, sleep disturbance, and their co-occurrence on smoking outcomes. *Psychology of Addictive Behaviors*. 2011; 25(2): 312–319. <http://dx.doi.org/10.1037/a0023128>. [PubMed: 21443301]
- Piper ME, Piasecki TM, Federman EB, Bolt DM, Smith SS, Fiore MC, et al. A multiple motives approach to tobacco dependence: The Wisconsin Inventory of Smoking Dependence Motives (WISDM-68). *Journal of Consulting and Clinical Psychology*. 2004; 72(2):139–154. <http://dx.doi.org/10.1037/0022-006x.72.2.139>. [PubMed: 15065950]
- Pomerleau CS, Carton SM, Lutzke ML, Flessland KA, Pomerleau OF. Reliability of the fagerstrom tolerance questionnaire and the fagerstrom test for nicotine dependence. *Addictive Behaviors*. 1994; 19(1):33–39. [http://dx.doi.org/10.1016/0306-4603\(94\)90049-3](http://dx.doi.org/10.1016/0306-4603(94)90049-3). [PubMed: 8197891]
- Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect effects in simple mediation models. *Behavior Research Methods, Instruments, & Computers*. 2004; 36(4):717–731. <http://dx.doi.org/10.3758/bf03206553>.
- Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. *Behavior Research Methods*. 2008; 40(3):879–891. [PubMed: 18697684]
- Preacher KJ, Kelley K. Effect size measures for mediation models: Quantitative strategies for communicating indirect effects. *Psychological Methods*. 2011; 16(2):93–115. <http://dx.doi.org/10.1037/a0022658>. [PubMed: 21500915]
- Riedel BW, Durrence HH, Lichstein KL, Taylor DJ, Bush AJ. The relation between smoking and sleep: The influence of smoking level, health, and psychological variables. *Behavioral Sleep Medicine*. 2004; 2(1):63–78. http://dx.doi.org/10.1207/s15402010bsm0201_6. [PubMed: 15600225]
- Rieder A, Kunze U, Groman E, Kiefer I, Schoberberger R. Nocturnal sleep-disturbing nicotine craving: A newly described symptom of extreme nicotine dependence. *Acta Medica Austriaca*. 2001; 28(1):21–22. [PubMed: 11253627]
- Roth T. Insomnia: Definition, prevalence, etiology, and consequences. *Journal of Clinical Sleep Medicine*. 2007; 3(5 Suppl):S7–S10. [PubMed: 17824495]
- Rothman, KJ., Greenland, S., Lash, TL. *Modern epidemiology*. 3. Philadelphia: Lippincott Williams & Wilkins; 2008.
- Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. *Sleep*. 2000; 23(2):243–308. [PubMed: 10737342]
- Scharf DM, Dunbar MS, Shiffman S. Smoking during the night: Prevalence and smoker characteristics. *Nicotine & Tobacco Research*. 2008; 10(1):167–178. <http://dx.doi.org/10.1080/14622200701767787>. [PubMed: 18188757]
- Sheikh JI, Woodward SH, Leskin GA. Sleep in post-traumatic stress disorder and panic: Convergence and divergence. *Depression and Anxiety*. 2003; 18(4):187–197. <http://dx.doi.org/10.1002/da.10066>. [PubMed: 14661188]
- Short NA, Mathes BM, Gibby B, Oglesby ME, Zvolensky MJ, Schmidt NB. Insomnia symptoms as a risk factor for cessation failure following smoking cessation treatment. *Addiction Research & Theory*. 2017; 25(1):17–23. [PubMed: 29104521]
- Tull MT, Aldao A. Editorial overview: New directions in the science of emotion regulation. *Current Opinion in Psychiatry*. 2015; 3:iv–ix. <http://dx.doi.org/10.1016/j.copsyc.2015.03.009>.
- USDHHS, U. S. D. o. H. H. S. *Frontiers of knowledge in sleep & sleep disorders: Opportunities for improving health and quality of life*. Bethesda, MD: National Institutes of Health; 2004.
- Watson D, O'Hara MW, Simms LJ, Kotov R, Chmielewski M, McDade-Montez EA, et al. Development and validation of the Inventory of Depression and Anxiety Symptoms (IDAS). *Psychological Assessment*. 2007; 19(3):253–268. <http://dx.doi.org/10.1037/1040-3590.19.3.253>. [PubMed: 17845118]
- Wetter DW, Young TB. The relation between cigarette smoking and sleep disturbance. *Preventive Medicine*. 1994; 23(3):328–334. <http://dx.doi.org/10.1006/pmed.1994.1046>. [PubMed: 8078854]
- Whiteside U, Chen E, Neighbors C, Hunter D, Lo T, Larimer M. Difficulties regulating emotions: Do binge eaters have fewer strategies to modulate and tolerate negative affect? *Eating Behaviors*. 2007; 8(2):162–169. <http://dx.doi.org/10.1016/j.eatbeh.2006.04.001>. [PubMed: 17336786]

- Yoo S-S, Gujar N, Hu P, Jolesz FA, Walker MP. The human emotional brain without sleep — A prefrontal amygdala disconnect. *Current Biology*. 2007; 17(20):R877–R878. <http://dx.doi.org/10.1016/j.cub.2007.08.007>. [PubMed: 17956744]
- Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. *Nicotine & Tobacco Research*. 2008; 10(12):1691–1715. <http://dx.doi.org/10.1080/14622200802443569>. [PubMed: 19023823]

HIGHLIGHTS

- Emotion dysregulation mediated insomnia and NR smoking outcome expectancies.
- Emotion dysregulation mediated insomnia and NR smoking motives.
- Emotion dysregulation mediated insomnia and HC smoking abstinence expectancies.

Fig. 1.

Conceptual model. *Note.* *a* path=effect of X on M; *b* paths = effect of Mon Y_i; *c* paths = total effect of X on Y_i; *c'* paths = direct effect of X on Y_i controlling for M. Four separate paths were conducted (Y₁₋₄) with the predictor (X). Covariates included participant sex, number of cigarettes smoked per day, and psychopathology.

Table 1Descriptive statistics and bivariate correlations between study variables ($N=126$).

Variable	Mean/ (SD/%)	1	2	3	4	5	6	7	8	9	10
1. Participant sex ^a	55 (43.7%)	–									
2. CPD ^a	14.68 (6.08)	–0.00	–								
3. Psychopathology ^a	50 (39.7%)	0.07	0.02	–							
4. Tobacco Dependence	4.67 (1.49)	0.05	0.53***	0.07	–						
5. Insomnia Symptoms ^b	12.33 (6.28)	–0.11	0.12	0.42***	0.15	–					
6. Emotion Dysregulation ^c	71.37 (23.10)	0.09	0.14	0.33***	0.17	0.57***	–				
7. Smoking Expectancies ^d	4.92 (2.44)	0.21*	0.25**	0.22*	0.04	0.28***	0.47***	–			
8. Smoking Motives ^d	4.40 (1.65)	0.18*	0.26**	0.13	0.14	0.20*	0.37***	0.81***	–		
9. Somatic Symptoms Abstinence Expectancies ^d	7.08 (7.66)	0.11	0.13	0.38***	0.14	0.35***	0.36***	0.30**	0.30**	–	
10. Harmful Consequences Abstinence Expectancies ^d	7.64 (8.66)	0.08	0.22*	0.34***	0.31	0.37***	0.50***	0.38***	0.37***	0.70***	–

Note. Participant sex: % listed as females (Coded: 0 = male and 1 = female); CPD = number of cigarettes smoked per day per the Timeline Follow-back; Psychopathology = presence/absence of current (past year) psychopathology per the Structured Clinical Interview—Non-Patient Version for DSM-IV (Coded: 0 = no; 1 = yes; First et al., 2007); Tobacco Dependence = Fagerström Test for Nicotine Dependence (Heatherton et al., 1991); Insomnia Symptoms = Inventory of Depression and Anxiety–Insomnia subscale (Watson et al., 2007); Emotion Dysregulation = Difficulties with Emotion Regulation Scale (Gratz & Roemer, 2004); Smoking Expectancies = Smoking Consequences Questionnaire–Negative Reinforcement subscale (Brandon & Baker, 1991); Smoking Motives = Wisconsin Inventory of Smoking Dependence Motives–Negative Reinforcement subscale (Piper et al., 2004); Somatic Symptoms Abstinence Expectancies = Smoking Abstinence Expectancies Questionnaire–Somatic Symptoms subscale (Abrams et al., 2011); Harmful Consequences Abstinence Expectancies = Smoking Abstinence Expectancies Questionnaire–Harmful Consequences subscale (Abrams et al., 2011).

 $p < 0.001$.

**
 $p < 0.01$.

*
 $p < 0.05$.

^aCovariate.

^bPredictor.

^cMediator.

^dCriterion.

Indirect effect of insomnia symptoms on negative reinforcement smoking outcome expectancies, negative reinforcement smoking motives, and negative expectancies from brief smoking abstinence (somatic symptoms and harmful consequences).

Table 2

Y	Path	R ²	b	SE	t	p	CI (l)	CI (u)	κ ²
1	IDAS-IN → DERS (a)	0.36	2.00	0.30	6.68	<0.001	1.218	2.788	
	DERS → SCQ-NR (b)	0.29	0.04	0.01	4.91	<0.001	0.015	0.068	
	IDAS-IN → SCQ-NR (c)		0.01	0.04	0.12	0.907	-0.098	0.107	
	IDAS-IN → SCQ-NR (c)	0.19	0.09	0.04	2.47	0.015	-0.005	0.181	
	IDAS-IN → DERS → SCQ-NR (a * b)		0.08	0.03			0.029	0.169	0.22
2	DERS → WISDM-NR (b)	0.20	0.02	0.01	3.15	0.002	0.004	0.042	
	IDAS-IN → WISDM-NR (c)		0.00	0.03	0.01	0.995	-0.074	0.074	
	IDAS-IN → WISDM-NR (c)	0.14	0.05	0.03	1.85	0.067	-0.019	0.112	
	IDAS-IN → DERS → WISDM-NR (a * b)		0.05	0.02			0.010	0.101	0.16
	DERS → SAEQ-SOM (b)	0.23	0.06	0.03	1.67	0.098	-0.032	0.143	
3	IDAS-IN → SAEQ-SOM (c)		0.18	0.13	1.41	0.161	-0.155	0.517	
	IDAS-IN → SAEQ-SOM (c)	0.21	0.29	0.11	2.64	0.009	0.003	0.581	
	IDAS-IN → DERS → SAEQ-SOM (a * b)		0.11	0.08			-0.069	0.333	0.11
	DERS → SAEQ-HARM (b)	0.31	0.14	0.04	4.00	<0.001	0.049	0.235	
	IDAS-IN → SAEQ-HARM (c)		0.08	0.14	0.56	0.579	-0.283	0.435	
4	IDAS-IN → SAEQ-HARM (c)	0.22	0.36	0.12	2.91	0.004	0.036	0.687	
	IDAS-IN → DERS → SAEQ-HARM (a * b)		0.29	0.10			0.062	0.595	0.22

Note. Path *a* is equal in all cases Y1-4; therefore, it presented only once to avoid redundancies. N for analyses is 126 cases. The standard error and 99% CI for the indirect effects (*a* * *b*) are obtained through bootstrapping with 10,000 re-samples. *a* path = effect of X on M; *b* paths = effect of X on Y; *c*' paths = direct effect of X on Y; *c* paths = total effect of X on Y. IDAS-IN = Inventory of Depression and Anxiety-Insomnia subscale (Watson et al., 2007); DERS = Difficulties with Emotion Regulation Scale (Grazz & Roemer, 2004); SCQ-NR = Smoking Consequences Questionnaire-Negative Reinforcement subscale (Brandon & Baker, 1991); WISDM-NR = Wisconsin Inventory of Smoking Dependence Motives-Negative Reinforcement subscale (Piper et al., 2004); SAEQ-SOM = Smoking Abstinence Expectancies Questionnaire-Somatic Symptoms subscale (Abrams et al., 2011); SAEQ-HARM = Smoking Abstinence Expectancies Questionnaire-Harmful Consequences subscale (Abrams et al., 2011). Covariates included participant sex, number of cigarettes smoked per day, and psychopathology.